Issue |
J Extra Corpor Technol
Volume 40, Number 2, June 2008
|
|
---|---|---|
Page(s) | 130 - 134 | |
DOI | https://doi.org/10.1051/ject/200840130 | |
Published online | 15 June 2008 |
Abstract
Argatroban in Short-Term Percutaneous Ventricular Assist Subsequent to Heparin-Induced Thrombocytopenia
* Vanderbilt Heart Institute, Vanderbilt University Medical Center, Nashville, Tennessee
† Division of Perfusion Services, Vanderbilt University Medical Center, Nashville, Tennessee
‡ Department of Cardiothoracic Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee
Address correspondence to: David P. Webb, Chief/Program Director, Perfusion, Vanderbilt University Medical Center, 2971 TVC 1211 22nd Avenue SO, Nashville, TN 37232. E-mail: david.webb@vanderbilt.edu
Heparin-induced thrombocytopenia paradoxically is a transient pro-thrombotic disorder triggered by heparin exposure. If not treated appropriately, it can be life threatening because of its related thromboembolic complications. In particular, it presents a unique challenge in patients needing extracorporeal life support, because anticoagulation is essential for safe management. This case report describes the safe, efficacious use of Argatroban during short-term support of a patient with a percutaneously inserted left ventricular assist TandemHeart device.
Key words: heparin-induced thrombocytopenia / Argatroban / TandemHeart / percutaneous ventricular assist device (pVAD)
© 2008 AMSECT
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.